In addition, Astrin was found to interact with MYCBP to promote the transcriptional activity of c-MYC, which could promote cell proliferation via upregulating c-MYC targeted genes including CDC20, CDC25C, breast-cancer susceptibility gene (BRCA) 1, and BRCA2 in triple-negative breast cancer (Li et al., 2019). This evidence concerns the gene MYC and triple-negative breast carcinoma.